Market Overview

Celsion Corp Says Continuing Phase 2 Study


Celsion Corporation (NASDAQ: CLSN), a leading oncology drug development company, today announced the presentation of Phase I results from the Company's Phase I/II DIGNITY study of ThermoDox(R) in Breast Cancer Recurrences at the Chest Wall at the ESMO 2012 Congress, the annual conference for the European Society of Medical Oncology held in Vienna, Austria September 28 to October 2, 2012. The presentation, titled "Breast Cancer Recurrences at the Chest Wall (BCRCW) When Standard Treatments (Tx) Have Failed: Lyso-thermosensitive liposomal doxorubicin (LTLD) + Mild Local Hyperthermia (MLH)," was delivered by Professor Hope S. Rugo, MD, from the UCSF School of Medicine, and provided a clinical update of the Phase I/II DIGNITY trial studying

Posted-In: News FDA


Related Articles (CLSN)

View Comments and Join the Discussion!

Get Benzinga's Newsletters